U.S. News Room
April 26, 2022
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
Download
April 19, 2022
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download
February 21, 2022
ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast Cancer
Download